hVIVO plc Exercise of Share Options (5484D)

TIDMHVO

RNS Number : 5484D

hVIVO plc

26 June 2019

HVIVO PLC

("hVIVO" or the "Company")

Exercise of Share Options

London, UK, 26 June 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 6,238 new ordinary shares of 5 pence each (the "New Ordinary Shares").

Admission to trading on AIM of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 3(rd) July 2019.

Following Admission, the total number of ordinary shares with voting rights in issue will be 83,002,384 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

For further information please contact:

 
 hVIVO plc 
 Trevor Phillips (Executive Chairman)                     [phone] 
 Fleur Wood (EVP, Investor Relations & Communications) 
 Numis Securities Limited                                  [phone] 
 Freddie Barnfield (Nominated Adviser) 
 James Black (Corporate Broking) 
 
 FTI Consulting 
 Simon Conway / Victoria Foster Mitchell                  [phone] 
 

Notes to Editors:

hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

IOEEQLFLKQFBBBQ

(END) Dow Jones Newswires

June 26, 2019 11:10 ET (15:10 GMT)